Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study

Abstract

Ivosidenib is an approved drug for relapsed or refractory IDH1 mutant AML patients. The goal of the present work is to develop and validate an LC-MS/MS method for the quantitation of ivosidenib in mice dried blood spots (DBS) as per regulatory guideline in the linearity range of 1.10–3293 ng/mL. To date there is no bioanalytical method reported for quantitation of ivosidenib. The chromatographic resolution of ivosidenib and internal standard (warfarin) was achieved on a C₁₈ column with an isocratic mobile phase. All validation parameters met the acceptance criteria. The intra- and inter-day precision was in the range of 2.79–10.5 and 5.76–9.02%, respectively. Ivosidenib was stable for 3 freeze/thaw cycles, up to 7 days at room temperature and for one month at −80°C. The applicability of the validated method is shown in a mice pharmacokinetic study. Ivosidenib was quantifiable up to 24 and 36 h following intravenous and oral administration to mice, respectively. The oral bioavailability was 48%. Comparison of DBS vs. plasma concentrations of ivosidenib showed excellent correlation, indicating DBS can be used as an alternative for plasma for pharmacokinetic analysis.

Key words

lvosidenib - dried blood spot - LC-MS/MS - method validation - mice blood - pharmacokinetics

• References

• 1 Buege MJ, DiPippo AJ, DiNardo CD. Evolving treatment strategies for elder leukemia patients with IDH mutations. Cancers 2018; 10: 187
• 2 Popovici-Muller J, Lemieux RM, Artin E. et al. Discovery of AG-120 (Ivosidenib): A first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 2018; 9: 300-305
• 3 Tibsovo (ivosidenib) prescribing information, Agios Pharmaceuticals, Inc, July 2018. Available at www.accessdata.fda.gov Accessed November 29, 2018
• 4 Chernonosov A. The use of dried blood spot for the quantitation of antihypertensive drug. International Journal of Analytical Chemistry 2018 Article ID-3235072
• 5 Lim MD. Dried blood spots for global health diganostics and surveillance: opportunities and challenges. American Journal of Tropical Medicine 2018; 99: 256-265
• 6 Sulochana PS, Daram P, Srinivas NR. et al. Review of DBS methods as a quantitative tool for anticancer drugs. Biomedical Chromatography 2019; 33: e4445
• 7 Enderle Y, Forester K, Burhenne J. Clinical feasibility of dried blood spots: analytics, validation, and applications. Journal of Pharmaceutical and Biomedical Analysis 2018; 130: 231-243
• 8 Brindle E, Lillis L, Barney R. et al. Measurement of micronutrient deficiency associated biomarkers in dried blood spots using a multiplexed immunoarray. PLoS One 2019; 14: e0210212
• 9 Freeman JD, Rosman LM, Ratcliff JD. et al. State of the science of dried blood spots. Clinical Chemistry 2018; 64: 656-679
• 10 US DHHS, FDA, CDER, CVM. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). 2018. Rockville, MD, USA:
• 11 Srinivas NR. Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples?. Bioanalysis 2016; 8: 607-610